Normal function · from ai-gene-review (Q9BYX4, commit 79fe13b38970) · AI-generated, not KB evidence

Interferon-induced helicase C domain-containing protein 1 (IFIH1/MDA5) is a cytosolic RIG-I-like receptor that couples recognition of duplex RNA to type I interferon induction. It has two N-terminal caspase activation and recruitment domains (CARDs), a central DExD/H-box helicase core with an inserted domain, and a zinc-binding C-terminal regulatory domain. Unlike RIG-I, which reads the end of a duplex, MDA5 binds the internal stem of long double-stranded RNA and polymerises head-to-tail along it; ATP binding and hydrolysis drive assembly and disassembly of these filaments, giving a proofreading mechanism that makes signalling depend on duplex length rather than on a chemical mark at the RNA end. Filament formation clusters the CARDs, which nucleate MAVS prion-like polymers on the mitochondrial outer membrane and activate TBK1/IKBKE and IRF3/IRF7, inducing interferon-alpha/beta and pro-inflammatory cytokines; MDA5 itself relocalises from cytosol to mitochondria upon activation and ISGylation. MDA5 is required for the response to picornaviruses such as encephalomyocarditis virus, and contributes to responses to coronaviruses, flaviviruses and some DNA viruses. Which RNA actually engages MDA5 during infection is unresolved. Long viral replicative duplexes and viral mRNA lacking the host 2'-O-methyl cap mark activate it, but crosslinking of endogenous MDA5 in SARS-CoV-2- and encephalomyocarditis-virus-infected cells recovers almost exclusively cellular RNA, concentrated in introns and near inverted Alu repeats, and infection-induced splicing defects are sufficient to trigger it; on that evidence MDA5 has been proposed to monitor the fidelity of host RNA processing rather than to detect a pathogen-specific molecular pattern. The same ambiguity is visible in disease: gain-of-function IFIH1 variants cause Aicardi-Goutieres syndrome and Singleton-Merten-spectrum type I interferonopathies through sterile activation, and adenosine-to-inosine editing by ADAR1 exists in part to prevent MDA5 from responding to endogenous duplex RNA. Common IFIH1 variants are associated with type 1 diabetes and other autoimmune conditions.

MDA5 binds the internal stem of long double-stranded RNA and polymerises head-to-tail along it. Unlike RIG-I it reads duplex length rather than a terminal chemical mark, and it is the RNA-binding event that licenses everything downstream. The duplexes it engages in cells are not necessarily viral: iCLIP of endogenous MDA5 during SARS-CoV-2 and encephalomyocarditis virus infection recovers host transcripts, concentrated in introns and near inverted Alu repeats, which are themselves capable of base-pairing.
molecular function: double-stranded RNA binding · directly involved in: MDA-5 signaling pathway; cellular response to exogenous dsRNA · locations: cytosol
Duplex-RNA-stimulated ATP hydrolysis by the DExD/H helicase core. The ATPase does not act as a processive duplex unwindase; it drives the assembly and disassembly of MDA5 filaments, and this turnover is the proofreading step that makes signalling depend on duplex length. Helicase catalytic activity is dispensable for interferon induction by full-length MDA5, so the ATPase tunes rather than transmits the signal.
molecular function: ATP hydrolysis activity · directly involved in: MDA-5 signaling pathway · locations: cytosol
Ligand-activated innate immune receptor activity: ligand binding occurs in the cytosol, where filament assembly clusters the tandem CARDs; the clustered CARDs then nucleate MAVS polymers at the mitochondrial outer membrane and drive TBK1/IKBKE and IRF3/IRF7 activation, inducing interferon-alpha/beta. This is MDA5's defining role, and is recorded here with an explicit caveat: GO:0038187 is defined as combining with a pathogen-associated molecular pattern, and whether MDA5's activating ligand is pathogen-derived is unsettled. Viral mRNA lacking 2'-O-methylation and long viral duplexes activate it, but in infected cells the bound RNA is predominantly host, gain-of-function variants cause sterile interferonopathy, and ADAR1 editing exists to keep endogenous duplexes from triggering it.
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
IFIH1-Related Type 1 Interferonopathy causative germline gain of function
mechanism: Heterozygous IFIH1 Gain-of-Function Variants
Selective IgA Deficiency susceptibility
Type I Diabetes susceptibility germline
Dermatomyositis untyped
Associated
Vitiligo untyped
Associated
Aicardi-Goutieres Syndrome no genetic record
mechanism: AGS-related pathogenic variants
subtype: Aicardi-Goutieres syndrome 7
ClinGen gene–disease validity · snapshot 2026-10-03 · matched to entries by MONDO

An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.

ClinGen diseaseMOIClassificationdismech entry
IFIH1-related type 1 interferonopathy MONDO:0700262 AD Definitive
2024-08-23

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.